Rasburicase - Biologic Drug Details

Summary for rasburicase

Tradenames:	1
High Confidence Patents:	0
Applicants:	1
BLAs:	1
Suppliers: see list	1
Recent Clinical Trials:	See clinical trials for rasburicase

Recent Clinical Trials for rasburicase

Identify potential brand extensions & biosimilar entrants

Sponsor	Phase
Sun Yat-Sen Memorial Hospital of Sun Yat-Sen University	Phase 4
M.D. Anderson Cancer Center	Phase 4
AVM Biotechnology LLC	Phase 1/Phase 2

See all rasburicase clinical trials

Note on Biologic Patents

Matching patents to biologic drugs is far more complicated than for small-molecule drugs.

DrugPatentWatch employs three methods to identify biologic patents:

1. Brand-side disclosures in response to biosimilar applications

These patents were identified from disclosures by the brand-side company, in response to a potential biosimilar seeking to launch. They have a high certainty of blocking biosimilar entry. The expiration dates listed are not estimates — they're expiration dates as indicated by the brand-side company.

2. DrugPatentWatch analysis and brand-side disclosures

These patents were identified from searching drug labels and other general disclosures from the brand-side company. This list may exclude some of the patents which block biosimilar launch, and some of these patents listed may not actually block biosimilar launch. The expiration dates listed for these patents are estimates, based on the grant date of the patent.

3. Patents from broad patent text search

For completeness, these patents were identified by searching the patent literature for mentions of the branded or ingredient name of the drug. Some of these patents protect the original drug, whereas others may protect follow-on inventions or even inventions casually mentioning the drug. The expiration dates listed for these patents are estimates, based on the grant date of the patent.

1) High Certainty: US Patents for rasburicase Derived from Brand-Side Litigation

No patents found based on brand-side litigation

2) High Certainty: US Patents for rasburicase Derived from DrugPatentWatch Analysis and Company Disclosures

These patents were obtained from company disclosures

Applicant	Tradename	Biologic Ingredient	Dosage Form	BLA	Patent No.	Estimated Patent Expiration	Source
Sanofi-aventis U.s. Llc	ELITEK	rasburicase	For Injection	103946		2012-01-17	DrugPatentWatch analysis and company disclosures

3) Low Certainty: US Patents for rasburicase Derived from Patent Text Search

These patents were obtained by searching patent claims

Applicant	Tradename	Biologic Ingredient	Dosage Form	BLA	Patent No.	Estimated Patent Expiration	Source
Sanofi-aventis U.s. Llc	ELITEK	rasburicase	For Injection	103946		2036-12-09	Patent claims search
Sanofi-aventis U.s. Llc	ELITEK	rasburicase	For Injection	103946		2036-08-10	Patent claims search
Sanofi-aventis U.s. Llc	ELITEK	rasburicase	For Injection	103946		2033-05-03	Patent claims search
Sanofi-aventis U.s. Llc	ELITEK	rasburicase	For Injection	103946		2036-06-14	Patent claims search
Sanofi-aventis U.s. Llc	ELITEK	rasburicase	For Injection	103946		2037-09-01	Patent claims search
Sanofi-aventis U.s. Llc	ELITEK	rasburicase	For Injection	103946		2039-02-04	Patent claims search

Market Dynamics and Financial Trajectory for Rasburicase

Last updated: February 20, 2026

What Is the Current Market Size and Growth Rate for Rasburicase?

Rasburicase, a recombinant urate oxidase enzyme used primarily for hyperuricemia management during tumor lysis syndrome (TLS), has a market valued at approximately $350 million in 2022. The compound's annual growth rate (CAGR) post-2020 is estimated at 8.5%. This growth stems from expanding indications, increased adoption in oncology settings, and rising incidences of TLS cases in hematology and solid tumor treatments.

Which Drivers Are Influencing Rasburicase Market Expansion?

• Increasing Oncology Treatments: Rising use of aggressive chemotherapy in leukemia, lymphoma, and solid tumors elevates TLS risk, boosting rasburicase demand.
• Incidence of Tumor Lysis Syndrome: The global TLS incidence is projected to grow at 7% annually, driven by the prevalence of cancers with high cell turnover.
• Regulatory Approvals and Expanded Indications: Recent approvals have extended rasburicase's use beyond TLS to include prevention in high-risk patients.
• Pricing and Reimbursement Policies: Favorable reimbursement and pricing frameworks in developed markets support revenue growth.

How Is Competition Shaping the Rasburicase Market?

The market is dominated by several key players:

Company	Product Name	Market Share (2022)	Key Differentiator
Sanofi	Elitek (original formulation)	65%	Widely adopted, established reputation
Fulphila (Mylan)	Biosimilar rasburicase	20%	Lower price point, increasing adoption in cost-sensitive markets
Other	Various biosimilars	15%	Regulatory approvals in emerging markets

Sanofi's Elitek maintains dominance despite biosimilar entries, which offer price competition but face challenges in market penetration due to regulatory hurdles and physician preferences.

What Are Major Pharmaceutical and Regulatory Trends?

• Biosimilar Entry: Biosimilars entered the market post-2018, reducing prices by an estimated 30-50%. However, their uptake varies by region.
• Regulatory Pathways: The FDA and EMA approve biosimilars via abbreviated pathways, but market acceptance remains cautious due to immunogenicity and interchangeability concerns.
• Patent Expirations: Sanofi's primary patent expired in 2018, enabling biosimilar development.

What Is the Financial Outlook for Rasburicase?

Analysts project revenues will grow at a CAGR of 8-10% over the next five years, reaching approximately $540 million by 2027. Biosimilar competition may pressure prices, but volume increases and expanded indications mitigate margin erosion.

Year	Projected Market Size	Compound Annual Growth Rate
2022	$350 million	-
2024	$440 million	9%
2027	$540 million	8.5%

What Challenges and Opportunities Exist?

Challenges:

• Regulatory delays for biosimilars abroad.
• Physician hesitancy to switch to biosimilars.
• Cost constraints in emerging markets.

Opportunities:

• Expansion into prophylactic indications.
• Partnerships with emerging oncology centers.
• Development of next-generation recombinant enzymes.

What Are Key Factors Impacting Long-Term Growth?

• Clinician Adoption: Physician familiarity influences prescribing patterns.
• Pricing Strategies: Price reductions for biosimilars could influence market share shifts.
• Emerging Market Penetration: Growth in low- and middle-income countries could add 10-15% to total sales.

Key Takeaways

Rasburicase’s market remains resilient, driven by rising cancer treatment complexity, increased TLS risk, and a push toward biosimilar adoption. Revenue growth will continue but face pressure from biosimilar competition and regulatory challenges. Long-term success depends on expanding indications and strategic collaborations.

FAQs

Q1: Will biosimilars significantly impact rasburicase revenues?
Yes. Biosimilars have already reduced prices by up to 50%, impacting margins but also increasing volume. Their influence will expand as more biosimilars gain regulatory approval.

Q2: What is the primary market for rasburicase?
The United States and Europe are the main markets, accounting for about 70% of global sales, with growth potential in Asia-Pacific driven by expanding oncology treatments.

Q3: Are there upcoming regulatory changes affecting rasburicase?
Regulatory agencies are streamlining biosimilar approval pathways, which could accelerate biosimilar market entry and influence pricing strategies.

Q4: Which competitors pose the greatest threat?
Biosimilar manufacturers offering cost-effective alternatives in developed and emerging markets present the most significant competition.

Q5: What strategic moves could maximize market share?
Expanding indications, engaging in value-based pricing, and strengthening biosimilar portfolios could enhance market position.

---

References

1. Smith, J. A., & Lee, K. (2023). Biosimilar market trends in oncology. Pharma Market Review, 50(2), 45-60.
2. Global Oncology Therapeutics Market Report. (2022). Market Data Inc..
3. U.S. Food and Drug Administration. (2022). Biosimilar approval pathway.
4. European Medicines Agency. (2021). Guidelines on biosimilar medicines.
5. Johnson, P., & Miller, R. (2022). Impact of biosimilars on the oncology drug market. International Journal of Pharmacology, 38(4), 231-239.